Case Study

Patient Engagement: Early Cancer Detection Blood Draw

Test Tube Blood Samples GettyImages-177440807

Elligo Health Research® was tasked by a pharmaceutical company to recruit subjects for a Phase III study called DETECT-ASCEND 2, focusing on Plasma-Based CancerSEEK Testing. CancerSEEK is a liquid biopsy designed to detect various cancers in their early stages. Despite facing processing constraints with the central laboratory, which could only handle 55 samples daily, Elligo adopted a targeted decentralized approach.

They successfully enrolled 6,400 participants across 19 sites within 4.5 months. To manage limitations and ensure inclusivity, Elligo adjusted its enrollment targets to 5,391 subjects and extended enrollment by a month. Additionally, to meet sponsor requirements, they prioritized enrolling males aged 60 and above for the final two months.

Discover the other ways Elligo was able to assist the pharmaceutical company by downloading the case study below.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

Elligo Health Research®